Published in Infect Dis (Lond) on May 06, 2020
Tocilizumab for COVID-19: a real 'miracle drug'? Infect Dis (Lond) (2020) 0.75
Challenges in COVID-19: is pulmonary thromboembolism related to overall severity? Infect Dis (Lond) (2020) 0.75
Time course of anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. Infect Dis (Lond) (2020) 0.75
Early experience with COVID-19 patients at academic hospital in Southwestern United States. Infect Dis (Lond) (2020) 0.75
Tele-rounding in a university hospital pulmonary ward during the COVID-19 pandemic: a pilot study. Infect Dis (Lond) (2020) 0.75
Effect of recombinant human granulocyte colony-stimulating factor on lymphocyte subsets in patients with COVID-19. Infect Dis (Lond) (2020) 0.75
Increased CD4/CD8 ratio as a risk factor for critical illness in coronavirus disease 2019 (COVID-19): a retrospective multicentre study. Infect Dis (Lond) (2020) 0.75
Laboratory abnormalities related to prolonged hospitalization in COVID-19. Infect Dis (Lond) (2020) 0.75